Welcome to the Starpharma Investor Centre

Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform.

asx.jpg

View All
ASX Announcements

 

Update your
shareholder details

 

Download 
Annual Report

View 
Analyst coverage

 

Submit an Investor query

 

Register for email updates

Watch Starpharma's 2022 Annual General Meeting

  
   

Latest News & Announcements

Click here for news archive

VIRALEZE™ Nasal Spray Approved in Malaysia (ASX Announcement)

Jun 5th, 2023

Starpharma today announces that it has achieved regulatory approval for its antiviral nasal spray product, VIRALEZE™, in Malaysia. The registration will allow Starpharma and its commercial partners to market and sell the product in Malaysia, a country with a population of over 33 million.

Read More

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Apr 28th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2023 (Q3 FY23). Starpharma’s net operating cash outflows for the quarter were $4.9 million, and the closing cash balance as at 31 March 2023 was $38.9 million.

Read More

 

Reports & Presentations

Click here for financial reports archive

VIRALEZE™ Nasal Spray Approved in Malaysia (ASX Announcement)

Jun 5th, 2023

Starpharma today announces that it has achieved regulatory approval for its antiviral nasal spray product, VIRALEZE™, in Malaysia. The registration will allow Starpharma and its commercial partners to market and sell the product in Malaysia, a country with a population of over 33 million.

Read More

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Apr 28th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2023 (Q3 FY23). Starpharma’s net operating cash outflows for the quarter were $4.9 million, and the closing cash balance as at 31 March 2023 was $38.9 million.

Read More